According to Corneal dystrophies are a group of rare genetic, often progressive, eye disorders in which abnormal material often accumulates in the clear (transparent) outer layer of the eye (cornea). There are more than 20 different types of corneal dystrophies which are generally grouped into three categories.
The symptoms of corneal dystrophy depend upon the type of corneal dystrophy. Some people experience no symptoms. In others, the build-up of material in the cornea causes it to become opaque (not clear). This leads to blurred vision or vision loss. Many people also experience corneal erosion which causes mild to severe pain in the eye, light sensitivity, and feeling like something is in the eye.
Get FREE sample copy at:
The Corneal Endothelial Dystrophy market report also covers emerging drugs, current treatment practices, Corneal Endothelial Dystrophy market share of the individual therapies, current and forecasted Corneal Endothelial Dystrophy Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Corneal Endothelial Dystrophy treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Corneal Endothelial Dystrophy Market Key Facts
Corneal dystrophies can affect individuals of any age. Because some individuals do not have symptoms (asymptomatic), determining the true frequency of these disorders in the general population is difficult.
Through various secondary studies, it can be concluded Corneal dystrophies affect women and men in equal numbers, except for Fuchs corneal dystrophy which affects women about four times as often as men.
According to the study titled “Corneal Dystrophy” by Moshirfar et al., (2020) in the United States, less than 0.01% of Americans are affected by corneal dystrophy (CD). It also stated the findings of another study which showed that around 530 persons out of a million in the United States have an endothelial-type CD. Both genders are equally affected by CD, although it has been shown that Fuchs CD is more common in females.
Key Benefits of Corneal Endothelial Dystrophy Market Report
Corneal Endothelial Dystrophy market report provides an in-depth analysis of Corneal Endothelial Dystrophy Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
The Corneal Endothelial Dystrophy market report will help in developing business strategies by understanding the Corneal Endothelial Dystrophy Market trends & developments, key players, and future market competition that will shape and drive the Corneal Endothelial Dystrophy market in the upcoming years.
The Corneal Endothelial Dystrophy market report covers Corneal Endothelial Dystrophy’s current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Corneal Endothelial Dystrophy market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Corneal Endothelial Dystrophy market size is expected to increase during the forecast period owing to the rise in the number of prevalent cases in the 7MM.
The Corneal Endothelial Dystrophy market outlook section of the report helps to build a detailed comprehension of the historic, current and forecasted Corneal Endothelial Dystrophy market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Corneal Endothelial Dystrophy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Corneal Endothelial Dystrophy Epidemiology
As per the Delveinsight, the diagnosed prevalent cases of Corneal Endothelial Dystrophy is expected to increase in the 7MM during the forecast year, with an improvement in treatment pattern as well.
The Corneal Endothelial Dystrophy epidemiology section covers insights about the historical and current Corneal Endothelial Dystrophy patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Corneal Endothelial Dystrophy Drugs Uptake and Key Market Players
The Corneal Endothelial Dystrophy Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Corneal Endothelial Dystrophy market or expected to get launched in the market during the study period. The analysis covers Corneal Endothelial Dystrophy market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of the Corneal Endothelial Dystrophy market is anticipated to change in the coming years owing to the improvement in the research and development undertaking. There are few key players involved in developing the therapies for Corneal Endothelial Dystrophy which are expected to launch during the forecast period.
The key companies in the Corneal Endothelial Dystrophy market include:
Price Vision Group
And many others
Corneal Endothelial Dystrophy therapies covered in the report include Rhopressa, Glanatec, TTHX1114, and many others.
Table of Content
1. Key Insights
2. Executive Summary
3. Corneal Endothelial Dystrophy Competitive Intelligence Analysis
4. Corneal Endothelial Dystrophy Market Overview at a Glance
5. Corneal Endothelial Dystrophy Disease Background and Overview
6. Corneal Endothelial Dystrophy Patient Journey
7. Corneal Endothelial Dystrophy Epidemiology and Patient Population
8. Corneal Endothelial Dystrophy Treatment Algorithm, Current Treatment, and Medical Practices
9. Corneal Endothelial Dystrophy Unmet Needs
10. Key Endpoints of Corneal Endothelial Dystrophy Treatment
11. Corneal Endothelial Dystrophy Marketed Products
12. Corneal Endothelial Dystrophy Emerging Therapies
13. Corneal Endothelial Dystrophy Seven Major Market Analysis
14. Attribute Analysis
15. Corneal Endothelial Dystrophy Market Outlook (7 major markets)
16. Corneal Endothelial Dystrophy Access and Reimbursement Overview
17. KOL Views on the Corneal Endothelial Dystrophy Market.
18. Corneal Endothelial Dystrophy Market Drivers
19. Corneal Endothelial Dystrophy Market Barriers
21. DelveInsight Capabilities
*The table of contents is not exhaustive; the final content may vary.
Corneal Endothelial Dystrophy (CED) Epidemiology
DelveInsight’s Corneal Endothelial Dystrophy (CED)- Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Corneal Endothelial Dystrophy in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Latest Reports By Delveinsight –
Mitochondrial Myopathies Market Insight
DelveInsight’ s “Mitochondrial Myopathies Market Insights, Epidemiology and Market Forecast 2030” report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology and the Mitochondrial Myopathies market size, share, trends, and forecast for the seven major markets (i.e. the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd. 2432
City: Las Vegas
Country: United States